RBC Capital analyst Leonid Timashev raised the firm’s price target on Insmed (INSM) to $120 from $108 and keeps an Outperform rating on the shares after its Q2 results and discussion with its management. The firm continues to “sense enthusiasm” for a potential launch for brenso later this year, with everything on track for a potential approval on August 12th, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $133 from $124 at UBS
- Insmed Positioned for Growth: Buy Rating Backed by Brensocatib Launch and Strong Pipeline
- Insmed Reports Strong Growth and Strategic Advances
- Insmed’s Strong Financial Performance and Promising Drug Pipeline Drive Buy Rating
- Insmed reports Q2 EPS ($1.70), consensus ($1.31)